Spectrum of illness: Understanding biological patterns and relationships in chronic migraine

Neurology

Volumn 72, Issue 5 SUPPL. 1, 2009, Pages

  Aurora, Sheena K ^a  

^a Swedish Pain and Headache Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; IRON;

ALLODYNIA; ANXIETY DISORDER; ARTICLE; CHRONIC DAILY HEADACHE; DEPRESSION; DISEASE COURSE; DISEASE DURATION; ELECTROPHYSIOLOGY; EPISODIC MIGRAINE; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL DISEASE; HUMAN; MIGRAINE; PAIN THRESHOLD; PATHOGENESIS; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; SENSITIZATION; TRANSFORMED MIGRAINE; TRIGEMINAL NUCLEUS; BRAIN; CHRONIC DISEASE; REVIEW;

BRAIN; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; MIGRAINE DISORDERS;

EID: 62349121642     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31819749fd     Document Type: Article

References (16)

1. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000;13:277-283.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002;346: 257-270. Review.
3. Silberstein SD. Chronic daily headache. J Am Osteopath Assoc 2005;105(4 suppl 2):S23-S29.
4. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003;106:81-89.
5. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006;46:1334-1343.
6. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache 2007;47:996-1003.
7. Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001;41:629-637.
8. Goadsby PJ. Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002;22:107-111.
9. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62:788-790.
10. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group. Botulinium toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293-307.
11. Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache 2005;45:546-552.
12. Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 2007;27:111-117.
13. Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev Neurotherapeutics 2006;6:297-306. Review.
14. Burstein R, Jakubowski M. Implications of multimechanism therapy: when to treat? Neurology 2005;64(10 suppl 2):S16-S20.
15. Lovati C, D'Amico D, Rosa S, et al. Allodynia in different forms of migraine. Neurol Sci 2007;28(suppl 2):S220-S221.
16. Bigal ME, Krymchantowski AV. Emerging drugs for migraine prophylaxis and treatment. Med Gen Med 2006;8: 1-16.